Podcasts about cftr

Editor-in-Chief Cecelia E. Schmalbach, MD, MSc, is joined by senior author Bradford A. Woodworth, MD, and Associate Editor Dana L. Crosby, MD, MPH, to discuss how lipopolysaccharide can be used to generate a model of acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction in murine nasal airways as outlined in the paper “Lipopolysaccharide Causes Acquired CFTR Dysfunction in Murine Nasal Airways,” which published in the May 2025 issue of Otolaryngology–Head and Neck Surgery. They talk about CFTR as a potential driving process in recalcitrant chronic rhinosinusitis. Click here to read the full article.  

Jean-Pierre Houle débute ce podcast avec un sujet important : la sécurité. Que ce soit en milieu de travail ou sur la route, on fait le tour du sujet. On continue en direct de la Journée des Employeurs, qui s'est déroulée aujourd'hui au Centre de Formation du Transport Routier situé à Mirabel, et qui nous... The post 1er mai 2025 Jean-Pierre Houle et la Journée des Employeurs au CFTR appeared first on Truck Stop Québec.

In this 1682nd episode of Toronto Mike'd, Mike chats with radio veteran Paul Fisher about his years at Rogers Radio, particularly CHFI, and his foray into writing. There are great stories about Don Daynard, Erin Davis, CFTR and more. Toronto Mike'd is proudly brought to you by Great Lakes Brewery, Palma Pasta, Ridley Funeral Home, Silverwax, Yes We Are Open, Nick Ainis and RecycleMyElectronics.ca. If you would like to support the show, we do have partner opportunities available. Please email Toronto Mike at mike@torontomike.com

Thanks to our group sponsors: Rogers, Pattison Media, Corus Entertainment, iHeartRadio, Stingray, Vista Broadcasting, Harvard Media. The Following summary of winners is from Broadcast Dialogue. Pattison Media's 102.3 NOW! Radio (CKNO-FM) Edmonton is among the multiple winners at the 2024 Canadian Radio Awards.NOW! won Major Market Station of the Year, and Best On-Air Promotion (Major Market) for its “Swiftie-oke” contest, while Program Director Jay Stone captured Program Director of the Year (Major Market). The station was also the catalyst behind Best Community Service Initiative winner Alberta Day of Caring for Jasper, which saw the province's radio stations come together to raise more than $1.5M to support those impacted by this summer's wildfire.Evanov Communications' stations in Winnipeg won in multiple categories. Evanov Winnipeg's Adam West captured Program Director of the Year (Medium Market), while the Energy 106 (CHWE-FM) morning show, Wheeler in the Morning, won Best On-Air Team (Music) (Medium Market). Energy 106 and Z103.5 (CIDC-FM) Toronto also won Best Imaging Production (Large Market), while their joint entry for HOT 100.5 (CFJL-FM) Winnipeg and LITE 92.1 (CKPC-FM) Brantford won in the Medium Market category.Rogers Sports & Media's CHEZ 106 Ottawa also captured two awards, including Station of the Year (Medium Market) and Best Community Service Initiative (Medium Market) for its DEEDS promotion.In the small market categories, Fort St. John, BC independent station 100.1 Moose FM (CKFU-FM) picked up two awards. Program Director Chris Walker won Program Director of the Year (Small Market), while the station also won Best Podcast (Small Market) for Before the Peace, focused on telling the stories of the Indigenous and Métis peoples of B.C.'s Peace Region.Kahnawake, Que. community station K1037 The Monster (CKRK-FM) also claimed two awards. Paul Graiff won Best Anchor/Reporter (Small Market), while Mitch Craig captured Best Imaging Voice (Small Market).By network, Rogers Sports & Media led wins with 14, followed by Pattison Media with eight, while Evanov picked up a total of five wins. Bell Media won in four categories, with Corus Radio and Harvard Media each earning three awards. Vista Radio won two.Find a full list of this year's winners below. To listen to their award-winning audio and view this year's runners-up, head to CanadianRadioAwards.com.Best Anchor or Reporter – Sponsored by Burli Major MarketRichard Southern, 680 NewsRadio, (CFTR), Rogers Sports & Media, TorontoMedium MarketRichard Duggan, VOCM-AM, (VOCM), Stingray, St. John's, Newfoundland and LabradorSmall MarketPaul Graif, K103.7 The Monster, (CKRK), Mohawk Radio, KahnawakeBest Canadian Multi-Market Network ProgramMajor MarketFearless Fred, Q107 / Power 97 / Edge / Big 101, (CILQ / CFQC / CJKR / CIQB ), CorusMedium MarketSam McDaid – Country Nights, (CKQC / CJOK / CKXC / CKBY / CIKZ / CJQM / CKAT / CJDL), Rogers Sports & MediaSmall MarketNick Liard – Regional Midday Show, (CJRQ / CJQQ / CKFX ), Rogers Sports & MediaBest On-Air Team or Host (News/Talk/Sports)Major MarketAndrea Montgomery / Kelly Turner / Logan Stein / Tanya Blakeney / Phil Wood / Lauryn Heintz – Calgary Morning Show, 660 NewsRadio (CFFR), Rogers Sports & Media, Calgary, AlbertaMedium MarketBrett Megarry / Greg Mackling – The Start, 680 CJOB (CJOB), Corus, Winnipeg, ManitobaBest On-Air Team or Host (Music)Major MarketThe Roz & Mocha Show, KiSS 92.5 (CKIS), Rogers Sports & Media, Toronto, OntarioMedium MarketWheeler in the Morning, Energy 106 (CHWE), Evanov Communications, Winnipeg, ManitobaSmall MarketJason McCoy / Carey Moran, Pure Country 106 (CICX), Bell Media, Orillia, OntarioBest On-Air Solo Host (Music)Major MarketLauren Hunter, Sonic 102.9 (CHDI), Rogers Sports & Media, Edmonton, AlbertaMedium MarketKatherine Dines, MOVE 100 (CJMJ), Bell Media, Ottawa, OntarioSmall MarketRobyn Thomson, KiSS 99.3 (CKGB), Rogers Sports & Media, TimminsMusic Director of the YearMajor MarketKatie Stanners, KiSS 91.7 (CHBN), Rogers Sports & Media, Edmonton, AlbertaMedium MarketIan Sharek, Rogers Rock Radio, Rogers Sports & Media, Multiple MarketsSmall MarketCourtney Rae, 106.1 The Goat (CKLM), Vista Radio, Lloydminster, Alberta Program Director of the Year – Sponsored by Momentum Media Major MarketJay Stone, 102.3 NOW! Radio (CKNO), UP! 99.3 (CIUP), Pattison Media, Edmonton, AlbertaMedium MarketAdam West, Energy 106 (CHWE), HOT 100.5 (CFJL), Evanov Communications, Winnipeg, ManitobaSmall MarketChris Walker, 100.1 Moose FM (CKFU), Moose Media, Fort St John, British ColumbiaStation of The Year – Sponsored by David Kaye / Kayeman Productions Major Market102.3 NOW! Radio (CKNO), Pattison Media, Edmonton, AlbertaMedium MarketCHEZ 106 (CHEZ), Rogers Sports & Media, Ottawa, OntarioSmall Market100.5 Cruz FM (CHFT), Harvard Media, Fort McMurray, AlbertaSound of Success – Sponsored by Validate Audio AttributionMajor MarketWhat's In A Name / Booster Juice, Rogers Sports & Media, National Campaign, Canada-wideSmall MarketGo Rock Campaign (CFLB), Novacast Media, Lunenburg, Nova Scotia Best Achievement in Engineering – Sponsored by leanStream All MarketsDaryll Donais, Hot Country 103, (CKHZ), Acadia Broadcasting, Halifax, Nova ScotiaBest Community or Campus Station – Sponsored by Community Radio Fund of Canada Major MarketVIBE 105 (CHRY), Canadian Centre for Civic Media and Arts Development Inc., Toronto, OntarioSmall Market100.1 BayFM (CKVB), Bay of Islands Radio Inc. , Corner Brook, Newfoundland and LabradorBest Community Service Initiative – Sponsored By Broadcast Dialogue Major MarketAlberta Day Of Caring For Jasper, 102.3 NOW! (CKNO), UP! 99.3 (CIUP), Pattison Media, Edmonton, AlbertaMedium MarketDEEDS, 106.1 CHEZ (CHEZ), Rogers Sports & Media, Ottawa, OntarioSmall MarketSpirit Day, 101.3 the River (CKKN), 99.3 REWIND Radio (CKDV), Pattison Media, Prince George, British ColumbiaBest Imaging Production – Sponsored by Benztown Major MarketZ103.5, (CIDC), Energy 106, (CHWE), Evanov Communications, Toronto, Ontario / Winnipeg, ManitobaMedium MarketLITE 92.1, (CKPC), HOT 100.5, (CFJL), Evanov Communications, Brantford, Ontario / Winnipeg, ManitobaSmall MarketPure Country 105, (CKQM), Bell Media, Peterborough, OntarioBest Imaging VoiceMajor MarketCorri English / Allan Peck / Jeff McKnight, STAR 95.9, (CHFM), Rogers Sports & Media, Calgary, AlbertaMedium MarketDavid Kaye, 104.9 The Wolf, (CFWF), Harvard Media, Regina, SaskatchewanSmall MarketMitch Craig, K1037, The Monster, (CKRK), Mohawk Radio, KahnawakeBest Performance in a CommercialMajor MarketBob Johnstone, Amore Pasta – Love Pasta Again, The Eagle, (CKLR), Pattison Media, Courtenay, British ColumbiaMedium MarketDave Hiltz, FoCheezy, 107.5 Dave Rocks. (CJDV), Corus, Kitchener, OntarioSmall MarketBrian Viggiani, Georgian Bay Storage, LITE 99.3, (CJGB), Evanov Communications, Meaford, Ontario Best CommercialMajor MarketOodle / Noodle – Improve Your Noodle, Play 107, (CKPW), Harvard Media, Edmonton, AlbertaMedium MarketHealthy Smiles / The Tooth Is Out There, BIG105 FM, (CHUB), Pattison Media, Red Deer, AlbertaSmall MarketFouillard Carpets, POWER99, (CFMM), Pattison Media, Prince Albert, SaskatchewanBest On-Air Promotion – Sponsored by vcreative Major Market102.3 NOW! Radio, (CKNO), Pattison Media, Edmonton, Alberta Medium Market103.7 Virgin Radio, (CHBE), Bell Media, Victoria, British ColumbiaSmall Market94.1 CJOC, (CJOC), Vista Radio, Lethbridge, AlbertaBest PodcastMajor MarketSweethearts: Island Crime, Season 6, Rogers Frequency NetworkMedium MarketRadio des Petits Hiboux, U Multicultural, U RadioSmall MarketBefore The Peace, 100.1 Moose FM, (CKFU), Fort St. John, British ColumbiaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Broadcast from KSQD, Santa Cruz on 11-14-2024: Dr. Dawn discusses a severe national IV fluid shortage caused by Hurricane Helene's flooding of a Baxter International factory which has affected hospital operations and surgical schedules nationwide. She provides a comprehensive explanation of cystic fibrosis, detailing how genetic mutations affect mucus production and impact multiple body systems, particularly the lungs and digestive system. The show explores the daily challenges faced by cystic fibrosis patients and their families, from complex treatment routines to social and financial impacts. Dr. Dawn presents exciting breakthroughs in cystic fibrosis treatment, including new CFTR modulators, targeted antibiotics, and promising developments in stem cell therapy and genetic treatments. She discusses a new universal genomic test developed at UCSF that can identify nearly any pathogen in cerebrospinal fluid, potentially revolutionizing the diagnosis of neurological infections. Dr. Dawn advises a caller about retinal dystrophy, explaining the differences between various eye conditions and suggesting potential dietary and lifestyle interventions. The show concludes with a concerning report about the tenfold increase in congenital syphilis cases over the past decade.

Dr. Lisa Lubsch is a Clinical Professor in the Department of Pharmacy Practice at the Southern Illinois University Edwardsville School of Pharmacy and Clinical Pharmacy Specialist at SSM Health Cardinal Glennon Children's Hospital in St. Louis.  She provides care to children with cystic fibrosis and other pulmonary problems.  Dr. Lubsch received the B.S. and Doctorate of Pharmacy from the St. Louis College of Pharmacy and completed a pediatric specialty residency at the Texas Tech University Health Sciences Center School of Pharmacy. She is board certified in pediatric pharmacy and fellow in the Pediatric Pharmacy Association.

Longtime Music & Entertainment Reporter Rudy Blair talks about working overnights at The Fan 590 while doing weekends at All Hits 680 CFTR, his transition from pushing buttons to getting in front of the microphone/camera, his induction into TWO Halls of Fame, his favourite interviews [Phil Collins, Barry White], his *ahem* less enjoyable interviews [Steven Seagal, Adrien Grenier, Jewel, Gene Simmons], and his exceptional interactions with Dustin Hoffman/Gordon Lightfoot/Lionel Richie/Shakira/Michael Bublé/Sting! Join Rudy as he hosts the 8th annual Kiss Cystic Fibrosis Goodbye fundraiser on Sept 28th at The Opera House...for more info, donations and tickets please visit www.kisscfgoodbye dot com For everything Rudy, please visit Rudy Blair Entertainment Media at https://rudyblairmedia.com/ TORONTO LEGENDS is hosted by Andrew Applebaum at andrew.applebaum@gmail.com All episodes available at https://www.torontolegends.ca/episodes/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Recent developments in treatment for cystic fibrosis have targeted the underlying genetic defect and these have been life-changing for some patients. Kevin Southern from Alder Hey Children's Hospital in the UK is an Editor for the Cochrane Cystic Fibrosis Group and an author of the updated review of these corrective therapies, which was published in November 2023. Here he is to tell us about the review.

Recent developments in treatment for cystic fibrosis have targeted the underlying genetic defect and these have been life-changing for some patients. Kevin Southern from Alder Hey Children's Hospital in the UK is an Editor for the Cochrane Cystic Fibrosis Group and an author of the updated review of these corrective therapies, which was published in November 2023. Here he is to tell us about the review.

In this 1513th episode of Toronto Mike'd, Mike chats with radio veteran Jeff Chalmers about his years at CFTR, Q107, CBC, The Hog, Boom and more. Will Jeff corroborate John Gallagher's story about Labatts paying the Q107 morning show team 20k to not say Molson for one year? Toronto Mike'd is proudly brought to you by Great Lakes Brewery, Palma Pasta, Ridley Funeral Home, The Advantaged Investor podcast from Raymond James Canada, The Toronto Maple Leafs Baseball Team and RecycleMyElectronics.ca. If you would like to support the show, we do have partner opportunities available. Please email Toronto Mike at mike@torontomike.com

Dans sa chronique, Bobby Roy, enseignant au CFTR, nous présente Me Alexandre Gauthier du cabinet Cain Lamarre, qui pratique le droit des transports et qui répond à une panoplie de questions pertinentes en lien aux infractions les plus souvent rencontrées dans le camionnage. Nous enregistrons en direct chez Excellence Peterbilt de Drummondville et nous nous... The post 19 juin 2024 Bobby Roy du CFTR, Me Alexandre Gauthier, Excellence Peterbilt et Transport Petit appeared first on Truck Stop Québec.

Dans la chronique Ça roule avec Bobby Roy, présenté par le Centre de formation du transport routier (CFTR), les camions électriques sont à la une, spécialement le nouveau bolide électrique de Lion Électrique, et nous en discutons avec le vice-président camion et affaires publiques de Lion, Patrick Gervais. En deuxième période, nous revenons sur la... The post 5 juin 2024 Bobby Roy du CFTR, Patrick Gervais de Lion Électrique, le Super Party Camionneurs et Patrick Dubé appeared first on Truck Stop Québec.

Ça roule avec Bobby Roy du Centre de Formation du Transport Routier (CFTR), qui anime sa chronique avec Sébastien Roy, directeur adjoint du CFTR, et Chloé St-Amand, directrice générale de Camo-Route. Ensembles, ils nous parlent du programme d'alternance travail-études (ATE). On parle également avec Nicolas Viau, enseignant au DEP transport par camion. On poursuit avec... The post 22 mai 2024 Ça roule avec Bobby Roy du CFTR, Sébastien Roy, Chloé St-Amand et Nicolas Viau, Jean-François Maltais et Mathieu Lussier d'Extrem Chase Québec appeared first on Truck Stop Québec.

Ça roule avec Bobby Roy! Dans sa chronique du jour, Bobby nous explique le PEACVL avec François Lapointe, enseignant chargé de projet au CFTR. Claude Quirion prend la relève, en abordant le besoin de plaire ou la peur de déplaire! Nous terminons avec le salon de l'emploi du camionnage, la “Foire de l'Emploi”, qui se... The post 8 mai 2024 Ça roule avec Bobby Roy du CFTR – PEACVL – Claude Quirion et la Foire de l'Emploi de Québec appeared first on Truck Stop Québec.

Patrick Blanchette, directeur général du CFTR, et Chloé St-Amand, directrice générale de Camo-Route, discutent de leur partenariat. Sébastien Roy et Bobby Roy annoncent en direct sur TSQ le retour de Bobby sur les ondes dans la chronique culte “Ça Roule avec Bobby”. Jean Raymond présente la foire de l'emploi du 11 mai à Québec. François Lapointe, enseignant... The post 18 avril 2024 Patrick Blanchette, Chloé St-Amand, Sébastien Roy, Bobby Roy, Jean Raymond et François Lapointe en direct du CFTR appeared first on Truck Stop Québec.

In this 1414th episode of Toronto Mike'd, Mike chats with Austin Delaney about his start in radio on stations like CFNY and CFTR and his 34 years at CFTO / CTV Toronto. Toronto Mike'd is proudly brought to you by Great Lakes Brewery, Palma Pasta, Ridley Funeral Home, The Advantaged Investor podcast from Raymond James Canada and Electronic Products Recycling Association.

Check out this milestone episode as we return to Cystic Fibrosis from a more pediatric perspective! Don't sweat it as Dr. Ina St. Onge returns to walk us through newborn screening,  early clinic visits, and the nuances of CFTR modulator therapy. 

Cystic Fibrosis explained, including Cystic Fibrosis pathophysiology, as well as its common symptoms. We also cover how Cystic Fibrosis is diagnosed (including newborn screening,  sweat testing and genetic testing) as well as Cystic Fibrosis treatment (with CFTR modulators!). Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps: 0:00 What is Cystic Fibrosis?0:53 Cystic Fibrosis Pathophysiology5:55 Cystic Fibrosis Symptoms 7:19 Cystic Fibrosis Diagnosis9:29 Cystic Fibrosis TreatmentReferencesBMJ Best Practice (2023) Cystic Fibrosis. Available at https://bestpractice.bmj.com/topics/en-gb/403MSD Manuals Pro (2022) Cystic Fibrosis. Available at https://www.msdmanuals.com/professional/pediatrics/cystic-fibrosis-cf/cystic-fibrosisFenker, D (2018) A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322854/Cystic Fibrosis Trust (2022) UK Cystic Fibrosis Registry 2021 Annual Data Report. Available at https://www.cysticfibrosis.org.uk/news/key-findings-from-the-2021-cf-registry-reportElaine Yu; Sandeep Sharma (2022) Cystic Fibrosis. Available at https://www.ncbi.nlm.nih.gov/books/NBK493206/British Lung Foundation. Cystic Fibrosis statistics. Available at https://statistics.blf.org.uk/cystic-fibrosisAndrea H. Roe (2021) Gynecologic health care for females with cystic fibrosis.        Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607192/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

Please consider subscribing, rating and commenting on our podcast (Spotify). But you can hear our podcasts anywhere.Dr. John Schuen is the division Chief of Pediatric Aerodigestive Specialties at Helen DeVos Children's hospital in Grand Rapids.  He is also the director of the CF care center.  We're talking to Dr. Schuen to discuss all that they have going on for CF patients in Grand Rapids. And why he decided to become a CF doctor.You are a specialist in so many areas, in addition to CF, in sleep medicine as well.  Why did you decide to become a doctor, and specifically why did CF draw you in?I wanted to do this podcast to highlight all the great things that you and Dr. Susan Millard are doing and Dr. Johanna Zea-Hernandez. Overall how many patients do you have in the pediatric department and what are you seeing since the latest modulator came about in 2019?(Laura did have a cold through this podcast).--------------------------------John Schuen serves as division chief of Pediatric Aerodigestive Specialties at Helen DeVos Children's Hospital. Schuen provides medical care of children with complex pulmonary, respiratory related problems and sleep disorders. He also serves as medical director of the pediatric sleep laboratory, center director of cystic fibrosis care center at Helen DeVos Children's Hospital. He is board certified in pediatric pulmonology and sleep medicine.After matriculating from Albion College, Dr. Schuen earned his medical degree from Michigan State University College of Human Medicine. He completed his residency in pediatrics at the Cleveland Clinic and fellowship in pediatric pulmonology & sleep medicine at Johns Hopkins Hospitals.Dr. Schuen has been a member of numerous professional organizations including the American Academy of Pediatrics, the American College of Chest Physicians, the American Academy of Sleep Medicine, and the American Thoracic Society.  He serves on statewide and national committees devoted to advancing lung health in children such as the Cystic Fibrosis Newborn Screen Task Force as well as the Center Committee of the Cystic Fibrosis Foundation. The CF Care Center is also a member of the Cystic Fibrosis Learning Network as well as the Therapeutic Development Network. The Helen DeVos Children's Hospital CF Care center also collaborates with Michigan State University to create and foster new research in their new Cystic Fibrosis Translational Research Program. The Pediatric Pulmonary section recently launched the system's first Pediatric Pulmonary fellowship program and currently has two wonderful fellows. He chaired the Cystic Fibrosis Foundation's Center Committee for two consecutive terms during the pandemic and is ex officio of Spectrum Health West Michigan's Medical Group Committee of the Board.He has published multiple original journal articles, book chapters, reviews as well as delivered dozens of invited talks devoted to advancing the state of the art in child's lung and sleep health.Helen DeVos Children's Hospital: https://www.spectrumhealth.org/for-health-professionals/referrals-and-consultations/pulmonary-critical-care-and-sleep-medicine/cystic-fibrosis-clinicPlease consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website: https://thebonnellfoundation.orgBonnell Foundation email: thebonnellfoundation@gmail.comThanks to our sponsors:Vertex:  https://www.vrtx.comGenentech: https://www.gene.comViatris: https://www.viatris.com/en

La Conférence des Utilisateurs d'Isaac Instruments se poursuit aujourd'hui et pour cette occasion spéciale, nous parlons avec Brigitte Roy, cheffe du marketing Isaac, Sébastien Roy et Eric Trudel du CFTR, Jérôme Bossé de Brunswick Transport, Sébastien Desaulniers de Trans-west, Julien-Pierre Daigle, ingénieur en analyse de données Isaac, Jean-François Lemaire, spécialiste de solutions Isaac et le... The post 25 Octobre 2023 Live Isaac Instruments appeared first on Truck Stop Québec.

In this 1320th episode of Toronto Mike'd, Mike chats with Erik Tomas of Raceline Radio about his years at CFTR and The Fan, especially his time with Shotgun Tom Rivers. Toronto Mike'd is proudly brought to you by Great Lakes Brewery, Palma Pasta, Pumpkins After Dark, Ridley Funeral Home and Electronic Products Recycling Association.

Annaka Haynes is a nursing student who has had Cystic Fibrosis since she was 6 weeks old. Trikafta developed by Vertex Pharmaceuticals was first approved by the FDA on October 21, 2019. This treatment is a triple combination regimen for cystic fibrosis patients starting at ages 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.

The story of CityNews 680 begins with music.  Episode one of “CityNews 680: 30 Years in the Rearview” details the history of CFTR's metamorphosis from all hits radio to all news radio.  We meet some of the seminal voices from the early days of the all news era and hear about how the radio station changed the way we talk about breaking news, traffic and weather in Toronto.  

Laura Bonnell, the Host of the Living with cystic fibrosis podcast, does a solo podcast this time around. This is her story, life without CF, diagnosis (here comes CF ready or not) and starting a Foundation.  It turns out that her path was always aligned with cystic fibrosis, from meeting Dr. Francis Collins (former director of the NIH and one of the scientists who discovered the gene that causes CF).From news reporter to CF advocate.The Bonnell Foundation website: https://thebonnellfoundation.orgBonnell Foundation email: thebonnellfoundation@gmail.comThanks to our sponsors:Vertex:  https://www.vrtx.comGenentech: https://www.gene.comViatris: https://www.viatris.com/en

We'll be taking a break in May, June, and July while our host is on maternity leave. See you again in August!   This week on Pharm5: Vowst (SER-109) for recurrent C Diff Trikafta for CF in 2+ years Mounjaro for weight loss in diabetes Qalsody accelerated approval for ALS J&J talc baby powder settlement   Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD   References: FDA approves first orally administered fecal microbiota product for the prevention of recurrence of Clostridioides difficile infection. U.S. Food and Drug Administration. https://bit.ly/3Li7Cue. Published April 26, 2023. Accessed April 27, 2023. Feuerstadt P, Louie TJ, Lashner B, et al. Ser-109, an oral microbiome therapy for recurrent clostridioides difficile infection. New England Journal of Medicine. 2022;386(3):220-229. doi:10.1056/nejmoa2106516 Vowst [package insert]. Cambridge, MA: Seres Therapeutics, Inc.; 2023. FDA approves Trikafta for children ages 2 through 5 years with certain CF mutations. Cystic Fibrosis Foundation. https://bit.ly/44dP3QD. Published April 26, 2023. Accessed April 27, 2023. Lobo A. FDA expands its approval of Trikafta to cover younger children. Cystic Fibrosis News Today. https://bit.ly/3oSuhG0. Published April 27, 2023. Accessed April 27, 2023. CFTR modulator therapies. Cystic Fibrosis Foundation. https://bit.ly/3Az4epZ. Accessed April 27, 2023. Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in surmount-2. Eli Lilly and Company. https://bit.ly/3VkD9AE. Published April 27, 2023. Accessed April 27, 2023. Galvez-Jiminez N, Goyal NA, Cudkowicz ME. Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate. http://www.utdol.com. Updated May 17, 2022. Accessed May 19, 2022. Liu A. FDA awards Biogen's ALS Drug Qalsody an accelerated approval, following its experts' feedback this time. Fierce Pharma. https://bit.ly/3VaVwrC. Published April 25, 2023. Accessed April 27, 2023. FDA approves Qalsody™ (Tofersen) as the first treatment targeting a genetic cause of ALS. PR Newswire: press release distribution, targeting, monitoring, and marketing. https://bit.ly/3ADSe6N. Published April 25, 2023. Accessed April 27, 2023. Qalsody [package insert]. Cambridge, MA: Biogen, Inc.; 2023. J&J to retain all talc-related liabilities from litigation in US, Canada. Reuters. https://bit.ly/3HjTS10. Published April 27, 2023. Accessed April 27, 2023. Spector M, Knauth D. J&J unit files for second bankruptcy to pursue $8.9 billion talc settlement. Reuters. https://bit.ly/426xfoY. Published April 5, 2023. Accessed April 27, 2023.

Le sénateur nous parles dans sa chronique de sa rencontre avec la famille de noha. assassinée en septembre 2022 avec son fils de 4 ans aux mains d'un prédateur sexuel au long passé criminel et dont personne n'avait la responsabilité de le surveiller. Plusieurs autres sujets sont au menu. André Durocher de Trans-West lui nous... The post 18 Avril 2023 Sénateur Boisvenu – André Durocher et la Journée des employeurs au CFTR appeared first on Truck Stop Québec.

André Durocher directeur de la conformité et de la sécurité chez Trans-West nous parle aujourd'hui de ses fameux billboards d'avocats quioffrent des millions en compensations pour leurs clients, Francois Lapointe invite tous ceux et celles qui cherchent un emplois classe 1, classe 2, classe 3, mécaniciens d'assiter Mardi 18 avril prochain à la journée des... The post 11 Avril 2023 André Durocher de TransWest et Francois Lapointe du CFTR appeared first on Truck Stop Québec.

Le sénateur Boisvenu nous parle dans sa chronique de sa visite à NORAD, Cheyenne Montains de Colorado Spring et de la sécurité en Arctique; il nous décrit l'endroit. Nous parlons ensuite du duo Lamatti et Trudeau qui l'échappent encore avec les ballons. Lamatti, pour qui la justice n'est pas une priorité! On termine avec les... The post 14 février 2023 Sénateur Boisvenu, André Durocher de Trans-West et François Lapointe du CFTR appeared first on Truck Stop Québec.

Synopsis: Mike Cloonan is the President and CEO of Sionna Therapeutics, a life sciences company dedicated to developing therapies for people living with cystic fibrosis. They are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF. Mike has over 20 years of experience in biotech and healthcare, 14 of which were spent working at Biogen where he was focused on the business and commercial side of the company. In this episode, he provides his perspective on the right time for a company to build out a commercial team and hire a commercial leader, his learnings stepping into a CEO role for the first time, and the current landscape of cystic fibrosis and what drew him to work on such an important patient population. Biography: Mike is President and Chief Executive Officer of Sionna. He is a respected biotech leader with over 20 years of biopharma experience across global organizations. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the company's first product, and execution of a transformational, multi-billion dollar collaboration. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia, and SMA franchises. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Mike earned his MBA from the Darden Graduate School of Business Administration at the University of Virginia and a B.A. from College of the Holy Cross.

Emily has been sick for her entire life, but no one can seem to figure out why. Some doctors believe it's Cystic Fibrosis. Some doctors don't. She's been diagnosed with CF several times, and she has been undiagnosed with CF just as many. CFTR-related illness is complicated to say the least and Emily has been through the wringer trying to get to the bottom of it. The struggle gets even more real after Emily falls through a roof of an abandoned building and breaks her back! On the plus side, she got some pretty beautiful photos in the process.

Emily has been sick for her entire life, but no one can seem to figure out why. Some doctors believe it's Cystic Fibrosis. Some doctors don't. She's been diagnosed with CF several times, and she has been undiagnosed with CF just as many. CFTR-related illness is complicated to say the least and Emily has been through the wringer trying to get to the bottom of it. The struggle gets even more real after Emily falls through a roof of an abandoned building and breaks her back! On the plus side, she got some pretty beautiful photos in the process.

  Vidcast:  https://youtu.be/BM9C_nTcJR0   Cystic Fibrosis is due to a genetic mutation that leads to insufficient moisture in body secretions and thickened respiratory mucus.  Geneticists at New York's Stony Brook University and the Cold Spring Harbor Laboratory have now demonstrated the possibility of using gene therapy with so-called antisense oligonucleotides to create better functioning versions  of the cell water-controlling protein CFTR, short for cystic fibrosis transmembrane conductance regulator.  This will someday result in a set of more normally-functioning lungs, pancreas, liver, gastrointestinal tract, and reproductive organs for those with cystic fibrosis.   https://www.nature.com/articles/s41467-022-30668-y   #cysticfibrosis #cf #genetherapy #cftr #aso #antisenseoligotides  

Nothing brings radio to life like 'theater of the mind'. Yet the art of Storytelling is often an overlooked skill.

It's Week 4 of the NFL and Dynasty Owner season. This used to be the quarter pole of the season, but not with 17 games now. Steve Van Tassell (@SteveVT33) and Jay Pounds (@jaypoundsnfl), the hosts of the Dynasty Owner podcast, break down Week 3 and preview Week 4. First, they talk about the two Dynasty Owner Podcast Listener leagues and find out that the only two 3-0 teams in each league are playing each other in Week 4. There will be only one top team in each league after this week! After that, they look at a couple of recent Dynasty Owner trades involving future draft picks for players. Then, they offer up some Week 3 thoughts and preview Week 4. Find out which RB is the Player of the Week for both of them since neither one thought the other would pick that guy. They do have different Bust of the Week picks though. Finally, they make their weekly game selections and choose the same Upset of the Week and Lock of the Week. Tune in and find out who they have for those picks

Pulmonologists have noted an exciting “baby boom” among women with Cystic Fibrosis (CF) in the last several years. As Gretchen Winter, MD, explains, CFTR modulators have led to increased fertility and the prospect of family planning for those with CF. She discusses the unique concerns those with CF may have when making reproductive decisions, such as effective contraception; safety of CFTR modulator use during both pregnancy and breastfeeding; and the risk of passing on the genetic disease. She also presents the different pathways to parenthood available for women and men with CF.

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent's University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent's University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

September 2022: CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis

En direct de la France Patrick Pinson co-anime le show d'aujourd'hui et on voulait des nouvelles de l'ami René Labrie qui depuis son départ du CFTR de St-Jérôme est maintenant rendu dans la région de Granby et toujours aussi impliqué dans son milieu! André Tardif de TEC Transport est avec nous, Quand le DCE sera... The post 9 Juin 2022 Rene Labrie – Andre Tardif et Patrick Pinson appeared first on Truck Stop Québec.

The Pulm PEEPs (Kristina Montemayor and Dave Furfaro) host a panel of Cystic Fibrosis (CF) providers to discuss the current state of the disease, recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, and the evolving faces and … Continue reading →

Hosts: Medical Student: Brooke Pace Quertermous Faculty: Katie McKie, MD Faculty: Ryan Harris, Ph.D Peer Review: Rebecca Yang, MD; Janelle McGill, MD During this episode, you will learn that Cystic Fibrosis is more than just a lung disease. Individuals with CF are also at risk for malabsorption, maldigestion, intestinal obstruction, exercise intolerance, and other systemic abnormalities. Dr. Katie McKie, Director of Pediatric Pulmonology at Augusta University, joins Dr. Ryan Harris, Founder and Director of the LIVEP and CF researcher, and Medical Student Brooke Quertermous to discuss the impact of nutrition and exercise on children with CF. Specifically, they will:  Explain the mechanism by which CF affects digestion and absorption of nutrients Acknowledge the importance of frequent growth monitoring for children with CF. Understand the role of nutrient supplementation for children with CF, and when enteral nutrition is required. Describe why exercise intolerance occurs in CF and the necessity of regular exercise for these patients. FREE CME Credit (requires sign-in): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=8631 Thank you for listening to this episode from the Department of Pediatrics at the Medical College of Georgia. If you have any comments, suggestions, or feedback- you can email us at mcgpediatricpodcast@augusta.edu Remember that all content during this episode is intended for informational and educational purposes only. It should not be used as medical advice to diagnose or treat any particular patient. Clinical vignette cases presented are based on hypothetical patient scenariosWe look forward to speaking to you on our next episode of the MCG Pediatric Podcast.   References: Gajbhiye, R., et al., Cystic fibrosis transmembrane conductance regulator (CFTR) gene abnormalities in Indian males with congenital bilateral absence of vas deferens & renal anomalies. Indian J Med Res, 2016. 143(5): p. 616-23. AND Elborn, J.S., Cystic fibrosis. Lancet, 2016. 388(10059): p. 2519-2531.) (Kuk, K. and J.L. Taylor-Cousar, Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis, 2015. 9(6): p. 313-26.) (Farrell et al, Siret el al, Sims et al). Sullivan, J. S., & Mascarenhas, M. R. (2017). Nutrition: Prevention and management of nutritional failure in cystic fibrosis. Journal of Cystic Fibrosis, 16. doi:10.1016/j.jcf.2017.07.010 Committee On Practice And Ambulatory Medicine, & Workgroup, B. (2020, March 01). 2020 recommendations for Preventive Pediatric health care. Retrieved March 22, 2021, from https://pediatrics.aappublications.org/content/145/3/e20200013 Cystic Fibrosis Foundation, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis, J Pediatr 2009; 155(6 Suppl):S73-93.) (Nutrition Prevention and Management Article) (Mattar AC, Leone C, Rodrigues JC, Adde FV. Sweat conductivity: an accurate diagnostic test for cystic fibrosis? J Cyst Fibros. 2014 Sep;13(5):528-33. doi: 10.1016/j.jcf.2014.01.002. Epub 2014 Jan 31. PMID: 24485874.) Ameet Daftary, James Acton, James Heubi, Raouf Amin, Fecal elastase-1: Utility in pancreatic function in cystic fibrosis, Journal of Cystic Fibrosis, Volume 5, Issue 2, 2006, Pages 71-76,ISSN 1569-1993, Walkowiak, D. Sands, A. Nowakowska, R. Piotrowski, K. Zybert, K.H. Herzig, et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations J Pediatr Gastroenterol Nutr, 40 (2) (2005), pp. 199-201 Witt, H. (2003). Chronic pancreatitis and cystic fibrosis. Gut, 52(90002), 31ii-41. doi:10.1136/gut.52.suppl_2.ii31 Fielding, J., Brantley, L., Seigler, N., McKie, K. T., Davison, G. W., & Harris, R. A. (2015). Oxygen uptake kinetics and exercise capacity in children with cystic fibrosis. Pediatric Pulmonology, 50(7), 647-654. doi:10.1002/ppul.23189 Orenstein, D. (2018). The Relationship between CFTR Genotype and Exercise Tolerance in Cystic Fibrosis.. AnnalsATS, 15(2), 166. Marcotte JE, Canny GJ, Grisdale R, Desmond K, Corey M, Zinman R, Levison H, Coates AL. Effects of nutritional status on exercise performance in advanced cystic fibrosis. Chest. 1986 Sep;90(3):375-9. doi: 10.1378/chest.90.3.375. PMID: 3743150. Pastré, J., Prévotat, A., Tardif, C., Langlois, C., Duhamel, A., & Wallaert, B. (2014). Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC pulmonary medicine, 14(1), 1-8. Hulzebos, Erik H. J.1; Bomhof-Roordink, Hanna1,3; van de Weert-van Leeuwen, Pauline B.2; Twisk, Jos W. R.3; Arets, H. G. M.2; van der Ent, Cornelis K.2; Takken, Tim1 Prediction of Mortality in Adolescents with Cystic Fibrosis, Medicine & Science in Sports & Exercise: November 2014 - Volume 46 - Issue 11 - p 2047-2052 doi: 10.1249/MSS.0000000000000344 Ding S., Zhong C. (2020) Exercise and Cystic Fibrosis. In: Xiao J. (eds) Physical Exercise for Human Health. Advances in Experimental Medicine and Biology, vol 1228. Springer, Singapore. https://doi.org/10.1007/978-981-15-1792-1_26 Moorcroft AJ, Dodd ME, Morris J, Webb AK. Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial. Thorax. 2004 Dec;59(12):1074-80. doi: 10.1136/thx.2003.015313. PMID: 15563708; PMCID: PMC1746905. Pianosi P, Leblanc J, Almudevar A. Peak oxygen uptake and mortality in children with cystic fibrosis. Thorax. Jan 2005;60(1):50-54. LIVEP Contact: Reva Crandall at 706-721-5483.  

Pancreatic insufficiency. In children with CF, it's been associated with delayed development and increased odds of developing severe lung disease. How can it be more accurately diagnosed? And what does the evidence say about the effects of treatment with CFTR modulators?That's what we explore in this case-based podcast, with Dr. Vikesh Singh, Associate Professor of Medicine and Director of the Pancreatitis Center at Johns Hopkins Medical Institutions.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When should modulator therapy be stopped? When is it safe to continue?In this eCysticFibrosis Review podcast, Dr. Traci Kazmerski from UPMC Children's Hospital of Pittsburgh and Dr. Natalie West from Johns Hopkins University take us into the clinic to address these important questions.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions?That's the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children's National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

This episode of Drug Cards Daily is on the drug Trikafta. As of 2020 it is Brand only. Trikafta consists of three drugs which are elexacaftor, ivacaftor, tezacaftor. It is twice a day dosing with 2 tablets in the morning and 1 tablet (12 hours later) in the evening. The morning tablet is orange in color and consists of elexacaftor 100 mg + tezacaftor 50mg + ivacaftor 75 mg while the evening dose (which is a light blue colored tablet) consists of ivacaftor 150 mg. Currently the drug is approved for use in ages 12 years and older. The main concerns are patients must have the F508del mutation in the CFTR gene have healthy liver function. Patients without the F508del mutation will not benefit from this drug. The other concern is that CYP3A inducers and inhibitors affect this drug greatly so that should always be considered when starting a patient on this treatment. Go to DrugCardsDaily.com for episode show notes which consist of the drug summary, quiz, and link to the drug card for FREE! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. The main goal is to go over the Top 200 Drugs with the occasional drug of interest. Also, if you'd like to say hello, suggest a drug, or leave some feedback I'd really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on twitter @drugcardsdaily --- Send in a voice message: https://anchor.fm/drugcardsdaily/message

Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What's known about CFTR modulator effects on cystic fibrosis-associated liver disease? In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Division of Gastroenterology, Hepatology, and Nutrition at the Johns Hopkins Children's Center take us to the clinic to answer these and other questions crucial to the health of our patients with cystic fibrosis.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who's most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children's Hospital Colorado, part of the University of Colorado's Anschutz Medical Campus, takes us to the clinic to discuss some answers.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

On this episode we have the VP of CFTR, Elesa Berard, come on to talk about her upcoming race, trail conditions and what can we expect at the Peace River Hare Scramble in Bartow, FL.

The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition?In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital's Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings about CFTR modification can impact clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.